5097-82-5

Basic information

• Product Name: 1-PHENYL-1,4-DIHYDRO-5H-TETRAZOL-5-ONE
• Synonyms: 1-phenyl-2H-1,2,3,4-tetrazol-5-one;1-phenyl-2H-tetrazol-5-one
• CAS NO: 5097-82-5
• Molecular Formula: C₇H₆N₄O
• Molecular Weight: 162.15
• Mol File: 5097-82-5.mol
• Article Data: 35

Chemical Properties

• Boiling Point: 231.2°Cat760mmHg
• Flash Point: 93.6°C
• Appearance: /
• Density: 1.46g/cm³
• CAS DataBase Reference: 1-PHENYL-1,4-DIHYDRO-5H-TETRAZOL-5-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PHENYL-1,4-DIHYDRO-5H-TETRAZOL-5-ONE(5097-82-5)
• EPA Substance Registry System: 1-PHENYL-1,4-DIHYDRO-5H-TETRAZOL-5-ONE(5097-82-5)

Safety Data

• Hazardous Substances Data: 5097-82-5(Hazardous Substances Data)

Usage

Chemical structure

Tetrazole derivative

Potential uses

+ Central nervous system stimulant
+ Anxiolytic agent
+ Substrate in the synthesis of pharmaceutical compounds

Research applications

+ Convulsant agent to induce seizure activity in laboratory animals for the study of epilepsy and related disorders
+ Induce rapid seizures in animal models for biochemical and neurophysiological research

Other applications

+ Chemical intermediate in the synthesis of other organic compounds

Upstream product

• 613-90-1 benzoyl cyanide 
• 98-88-4 benzoyl chloride 
• 93524-73-3 5-<(4-methoxycarbonyl)phenoxy>-1-phenyltetrazole 
• 77924-18-6 5-(4-cyanophenoxy)-1-phenyl-1H-tetrazole 
• 180056-88-6 5-benzyloxy-1-phenyltetrazole 
• 109-99-9 tetrahydrofuran 
• 1455-92-1 5-methylsulfanyl-1-phenyl-1H-tetrazole 
• 17743-28-1 1-(4-amino-1-phenoxy)-5-phenyltetrazole 
• 17743-24-7 5-(4-methoxy-phenoxy)-1-phenyl-1H-tetrazole 
• 14210-25-4 5-Chloro-1-phenyltetrazole 
• 77924-20-0 4-(1-Phenyl-1H-tetrazol-5-yloxy)-benzaldehyde 
• 97209-47-7 5-(4-trifluoromethylphenoxy)-1-tetrazole 
• 77924-22-2 7-(1-Phenyl-1H-tetrazol-5-yloxy)-chromen-2-one 
• 77924-16-4 5-(8-Methanesulfonyl-naphthalen-2-yloxy)-1-phenyl-1H-tetrazole 

Downstream Products

• 6415-57-2 1,4-dihydro-1-hydroxymethyl-4-phenyltetrazol-5-one 
• 14210-25-4 5-Chloro-1-phenyltetrazole 
• 75430-97-6 1-(4-nitrophenyl)-4,5-dihydro-1H-1,2,3,4-tetrazol-5-one 
• 6415-51-6 1-morpholin-4-ylmethyl-4-phenyl-1,4-dihydro-tetrazol-5-one 
• 75430-98-7 1-phenyl-4-(phenylcarbamoyl)-5(4H)-tetrazolinone 
• 124313-55-9 1-(3-Oxo-butyl)-4-phenyl-1,4-dihydro-tetrazol-5-one 
• 6415-56-1 3-(5-oxo-4-phenyl-4,5-dihydro-tetrazol-1-yl)-propionitrile 
• 13444-10-5 1,4-Dihydro-1-phenyl-4-(2-propenyl)-5H-tetrazol-5-on 
• 95926-77-5 1-(2-Cyclohexen-1-yl)-1,4-dihydro-4-phenyl-5H-tetrazol-5-on 
• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 35727-21-0 1,4-dihydro-1-(2-hydroxethyl)-4-phenyl-5H-tetrazol-5-one 
• 233604-15-4 1-octyl-4-phenyl-1,4-dihydro-tetrazol-5-one 
• 233604-14-3 1-hexyl-4-phenyl-1,4-dihydro-tetrazol-5-one 
• 182251-87-2 4-(3-cyclopentylpropyl)-1-phenyl-5-tetrazolone 

Relevant articles and documents

Mechanisms in heterogeneous liquid-phase catalytic-transfer reduction: The importance of hydrogen-donor concentration

-

Tetrazole ethers from lignin model phenols: Synthesis, crystal structures, and photostability

The phenolic OH moiety in lignin is one of the key functional groups responsible for the photo-induced yellowing of mechanical wood pulps and papers. To evaluate new protective groups for the stabilization of lignin phenols, the model compounds, 2-methoxy-4-propylphenol (1) and 4-hydroxy-3-methoxyacetophenone (2) were reacted with 5-chloro-1-phenyl-1H-tetrazole to give the corresponding tetrazole ethers 1′ and 2′, respectively, that were then studied for their photostability. The synthesis of these ethers was more efficient than that of alkyl ethers because of less hydrolysis of the alkylating agent under the reaction conditions. Compounds 1′ and 2′ were fully characterized, including X-ray crystal structure analyses. Crystals of 1′ and 2′ were monoclinic of space groups P21/c and P21/a, respectively. For 1′: a = 9.8679(6), b = 16.708(1), c = 10.2841(6) A, β = 109.732(5)°, Z = 4. For 2′: a = 7.7212(2), b = 27.350(5), c = 14.569(3) A, β = 101.30(2)°, Z = 8. The structures were solved by direct methods and refined by full-matrix least-squares procedures to R = 0.039 (Rw = 0.046) for 2029 reflections with I ≥ 3σ(I) (for 1′), and to R = 0.055 (Rw = 0.073) for 3634 reflections with I ≥ 3σ(I) (for 2′). Compound 2′ was much more photostable than the precursor phenol on exposure to strong fluorescent light, while 1′ was only slightly more stable than the precursor phenol.

Synthesis and antileishmanial activity of 1,2,4,5-tetraoxanes against leishmania donovani

A chemically diverse range of novel tetraoxanes was synthesized and evaluated in vitro against intramacrophage amastigote forms of Leishmania donovani. All 15 tested tetraoxanes displayed activity, with IC50 values ranging from 2 to 45 μm. The most active tetraoxane, compound LC140, exhibited an IC50 value of 2.52 ± 0.65 μm on L. donovani intramacrophage amastigotes, with a selectivity index of 13.5. This compound reduced the liver parasite burden of L. donovani-infected mice by 37% after an intraperitoneal treatment at 10 mg/kg/day for five consecutive days, whereas miltefosine, an antileishmanial drug in use, reduced it by 66%. These results provide a relevant basis for the development of further tetraoxanes as effective, safe, and cheap drugs against leishmaniasis.

TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF

The present disclosure relates to compounds of formula (AI), (I), (AII), and (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (AI), (I), (AII), and (II), and use thereof, wherein R2, R3, R4, R5, R6, R7, R10, R11a, R11b, R12, R16, R19a, R19b, and R20 are described herein. Such compounds are envisioned useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, movement disorders, convulsive disorders, schizophrenin spectrum disorders, disorders of memory and/or cognition, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, or tinnitus etc.